About PHD finger protein 6
PHD finger protein 6 (PHF6) is a protein
from Homo sapiens identified by UniProt accession
Q8IWS0, 365 residues long.
MolForge cross-references it against 0 known binders and
225 disease associations.
Target properties
| Protein name | PHD finger protein 6 |
|---|
| UniProt accession | Q8IWS0 |
|---|
| Gene | PHF6 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 365 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (225)
Diseases linked to this target (Open Targets).
- Borjeson-Forssman-Lehmann syndrome · score 0.82
- neurodegenerative disease · score 0.54
- genetic disorder · score 0.51
- acute myeloid leukemia · score 0.49
- Intellectual disability · score 0.40
- T-cell acute lymphoblastic leukemia · score 0.38
- lymphoid neoplasm · score 0.37
- Endometrial Endometrioid Adenocarcinoma · score 0.37
- breast ductal adenocarcinoma · score 0.37
- Ovarian Endometrioid Adenocarcinoma with Squamous Differentiation · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8IWS0-F1 | alphafold | PREDICTED | 73.41 | — |
Amino-acid sequence (365 residues)
MSSSVEQKKG PTRQRKCGFC KSNRDKECGQ LLISENQKVA AHHKCMLFSS ALVSSHSDNE SLGGFSIEDV QKEIKRGTKL MCSLCHCPGA TIGCDVKTCH RTYHYHCALH DKAQIREKPS QGIYMVYCRK HKKTAHNSEA DLEESFNEHE LEPSSPKSKK KSRKGRPRKT NFKGLSEDTR STSSHGTDEM ESSSYRDRSP HRSSPSDTRP KCGFCHVGEE ENEARGKLHI FNAKKAAAHY KCMLFSSGTV QLTTTSRAEF GDFDIKTVLQ EIKRGKRMKC TLCSQPGATI GCEIKACVKT YHYHCGVQDK AKYIENMSRG IYKLYCKNHS GNDERDEEDE ERESKSRGKV EIDQQQLTQQ QLNGN
Explore PHD finger protein 6 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets